Real-time
Oslo Bors
03:02:31 2024-06-03 EDT
5-day change
1st Jan Change
43
NOK
+0.47%
+6.97%
+3.61%
Gentian Diagnostics : Invitation to presentation of second quarter results
August 18, 2022 at 06:54 am
Invitation to presentation of second quarter results
Subscribe
Company Name
GENTIAN DIAGNOSTICS ASA
ISN
NO0010748866
Market
Oslo Børs
Symbol
GENT
Gentian Diagnostics ASA will present its second quarter 2022 results on August
25th at 10.00 am.
The presentation will be held as a webcast and participants are invited to
register or join using the following link:https://attendee.gotowebinar.com/register/7206975888818806799
The webcast will be available on the company website after the presentation and
will be hosted by Hilja Ibert, CEO and Njaal Kind, CFO
More information:
Access the news on Oslo Bors NewsWeb site
Source
Gentian Diagnostics ASA
Provider
Oslo Børs Newspoint
Attachments
Original Link
Original Document
Permalink
Disclaimer
Gentian Diagnostics AS published this content on 18 August 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 18 August 2022 10:53:04 UTC .
Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024
04-30
CI
Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024
04-30
Gentian Diagnostics Asa Resolves to Elect Ms. Hilja Ibert as Chairperson of the Board of Directors
04-29
CI
Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO
04-29
CI
Gentian Diagnostics ASA Announces Resignation of Hilja Ibert as CEO, Effective on April 29, 2024
03-21
CI
Tomas Settevik Not to Stand for Re-Election as Chairperson of Gentian Diagnostics ASA, Effective April 29, 2024
03-21
CI
Gentian Diagnostics' CEO Resigns, Wins Recommendation to Succeed Chair
03-21
MT
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
02-09
CI
Transcript : Gentian Diagnostics ASA, Q4 2023 Earnings Call, Feb 09, 2024
02-09
Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors
12-18
CI
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-26
CI
Transcript : Gentian Diagnostics ASA, Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Gentian Diagnostics ASA Expands Product Portfolio With Turbidimetric Retinol-Binding Protein Immunoassay
23-09-29
CI
Gentian Diagnostics ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-24
CI
Transcript : Gentian Diagnostics ASA, Q2 2023 Earnings Call, Aug 24, 2023
23-08-24
Gentian Diagnostics ASA (OB:GENT) acquired Getica Ab from Erling Sundrehagen for SEK 2.8 million.
23-07-02
CI
Norway's Gentian Diagnostics Buys Sweden-based Getica in SEK3 Million Deal
23-06-15
MT
Gentian Diagnostics ASA (OB:GENT) entered into an agreement to acquire Getica Ab from Erling Sundrehagen for SEK 3 million.
23-06-14
CI
Transcript : Gentian Diagnostics ASA - Analyst/Investor Day
23-05-10
Transcript : Gentian Diagnostics ASA, Q1 2023 Earnings Call, May 05, 2023
23-05-05
Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-04
CI
Gentian Diagnostics ASA Announces Results from Study on Health Economic Impact of Use of GCAL CalProtectin Immunoassay for Early Detection of Infection in Intensive Care Patients
23-03-22
CI
Transcript : Gentian Diagnostics ASA, Q4 2022 Earnings Call, Feb 16, 2023
23-02-16
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
23-02-16
CI
Gentian Diagnostics ASA Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-16
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Companyâs product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
More about the company
Last Close Price
42.8
NOK
Average target price
57
NOK
Spread / Average Target
+33.18%
Consensus
1st Jan change
Capi.
+3.61% 62.78M -3.17% 8.22B +6.39% 5.72B +31.98% 5.67B -10.03% 4.11B -59.94% 2.68B +11.23% 2.68B -5.24% 2.37B +18.91% 2.06B -7.56% 1.8B
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1